MOBILE, Ala. (WKRG) — The University of South Alabama Mitchell Cancer Institute in Mobile is one of the few organizations splitting a $1,050,000 donation by the Breast Cancer Research Foundation of Alabama (BCRFA).
Funds being invested in the Mobile community by the BCRFA include three research projects at USA Mitchell:
- Dr. Natalie Gassman and Dr. Michelle Schuler
(2019 BCRFA Innovation Award Winners) – “Blockage of CHK1 and EGFR Signaling in
Triple Negative Breast Cancer to Enhance Anti-Tumor Efficacy” This project
focuses on how the lack of hormone and growth factor receptors in triple
negative breast cancer makes DNA damaging chemotherapies a first-line
treatment. Cardiotoxicity is a significant problem for these therapies. Dr.
Gassman and Dr. Scheler will test a novel combination of chemical inhibitors
that are only modestly effective on their own but have the potential in
combination to trigger death in triple negative cancer cells without cardiac
side effects.
- Dr. Gabrielle Roque and Dr. Casey Daniels (receiving
their second year of support for a collaborative research project between
O’Neal Comprehensive Cancer Center at UAB and USA Mitchell) – “Quantifying
Breast Cancer Patient Preferences and their Association with Financial Toxicity
during Treatment Decision-Making” In this project Dr. Roque and Dr. Daniels
plan to quantify the trade-offs that breast cancer patients make during
treatment decisions, with a focus on financial toxicity. Their central
hypothesis is that increased understanding of patient preferences, particularly
those associated with financial toxicity, through the evaluation of trade-offs,
will optimize shared decision making (SDM). Quantification of breast cancer
patient preferences will create opportunities for patient participation in
decision-making, aid clinicians in understanding patient perspective during
treatment decision-making, and ultimately achieve patient-centered, higher
value healthcare for women living with breast cancer.
- Dr. Gary Piazza and Dr. Clint Grubbs (Collaboration between O’Neal Comprehensive Cancer Center at UAB and USA Mitchell) – “A Novel Wnt/β-catenin Inhibitor for Breast Cancer Therapy” This research is based on results from a two-year project funded in 2017 by the BCRFA. From this research project, they found a very promising compound named MCI-715 strongly inhibited tumorigenesis in a mouse model of breast cancer. Funds from the BCRFA will be used to evaluate the activity of MCI-715 in animal model trials for aggressive ER-breast cancer, and compare results against the current standard-of-care drug.
This donation announcement makes a total of almost $10 million donated y BCRFA since 1996. Other organizations receiving funds
To learn more about BCRFA, click here.
Latest Stories:
- 5 Things To Do This Weekend: February 21-23
- Cat defies odds and survives arrow to the head
- Migrants on one-way flights out of McAllen help break airport’s travel record
- Connecting the past and present through music
- Kentucky teen dies in apparent animal attack
